4‑Year Experience of the Cardio-Oncology Center of Sechenov University: Single-Center Epidemiological Study

Aim. To present the four-year experience and the accomplishments of the Scientific and Practical Cardio-Oncology Center of the Sechenov University.

Material and methods. The records of patients referred for cardio-oncology consultation from January 2020 through March 2024 were retrospectively analyzed. The patients’ cardiovascular (CV) status was assessed at baseline and after optimizing the cardiac therapy during the antitumor treatment. The endpoints were the completion of all antitumor therapy courses and the level of overall and CV mortality.

Results. Among 233 enrolled patients (66% women), a considerable part belonged to the group of high/very high cardio-oncological risk (n=134, 57%). Various cardiovascular toxicities were observed in 22% of patients. At baseline, these patients significantly more frequently had heart failure and ischemic heart disease as well as previous radiation and chemotherapy. After the optimization of cardiac therapy, 88% of patients successfully completed all scheduled treatments. The overall mortality, including the CV mortality, was 14% (n=7).

Conclusion. Creation of cardio-oncological services allows considerably reducing the probability of adverse CV events during the antitumor therapy and successfully completing all scheduled treatments in most patients.

.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021;71(1):7–33. DOI: 10.3322/caac.21654

2. Ahmed T, Marmagkiolis K, Ploch M, Irizarry-Caro JA, Amatullah A, Desai S et al. The Year in Cardio-oncology 2022. Current Problems in Cardiology. 2023;48(1):101435. DOI: 10.1016/j.cpcardiol.2022.101435

3. Federal State Statistics Service. Health in Russia. 2023. Statistical book. - M.: Rosstat, 2023. - 179p. Доступно на: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf

4. Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. International Journal of Cardiology. 2019;280:163–75. DOI: 10.1016/j.ijcard.2019.01.038

5. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244

6. Belenkov Yu.N., Ilgisonis I.S., Kirichenko Yu.Yu., Murtuzaliev Sh.M. Cardio-oncology today: digest of the first European clinical guidelines (2022). Kardiologiia. 2023;63(7):3–15. DOI: 10.18087/cardio.2023.7.n2445

7. López-Fernández T, Farmakis D, Ameri P, Asteggiano R, De Azambuja E, Aznar M et al. European Society of Cardiology Core Curriculum for cardio-oncology. European Journal of Heart Failure. 2024;26(4):754–71. DOI: 10.1002/ejhf.3102

8. Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Shupenina E.Yu., Ballyuzek M.F., Barinova I.V. et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):152–233. DOI: 10.15829/1560-4071-2021-4703

9. Yu AF, Yadav NU, Manrique CR, Thaler HT, Hudis CA, Dang CT et al. Abstract 9317: Impact of Trastuzumab-Induced Cardiotoxicity and Subsequent Trastuzumab Interruption on Breast Cancer Outcome. Circulation. 2013;128(Suppl 22):Abstract 9317. DOI: 10.1161/circ.128.suppl_22.A9317

10. Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V et al. Activity and outcomes of a cardio-oncology service in the United Kingdom - a five-year experience. European Journal of Heart Failure. 2018;20(12):1721–31. DOI: 10.1002/ejhf.1292